382 related articles for article (PubMed ID: 31578311)
1. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Eichstadt S; Barriga M; Ponakala A; Teng C; Nguyen NT; Siprashvili Z; Nazaroff J; Gorell ES; Chiou AS; Taylor L; Khuu P; Keene DR; Rieger K; Khosla RK; Furukawa LK; Lorenz HP; Marinkovich MP; Tang JY
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578311
[TBL] [Abstract][Full Text] [Related]
2. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
So JY; Nazaroff J; Iwummadu CV; Harris N; Gorell ES; Fulchand S; Bailey I; McCarthy D; Siprashvili Z; Marinkovich MP; Tang JY; Chiou AS
Orphanet J Rare Dis; 2022 Oct; 17(1):377. PubMed ID: 36253825
[TBL] [Abstract][Full Text] [Related]
4. Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.
Lee SE; Lee SJ; Kim SE; Kim K; Cho B; Roh K; Kim SC
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33491668
[TBL] [Abstract][Full Text] [Related]
5. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.
Lwin SM; Syed F; Di WL; Kadiyirire T; Liu L; Guy A; Petrova A; Abdul-Wahab A; Reid F; Phillips R; Elstad M; Georgiadis C; Aristodemou S; Lovell PA; McMillan JR; Mee J; Miskinyte S; Titeux M; Ozoemena L; Pramanik R; Serrano S; Rowles R; Maurin C; Orrin E; Martinez-Queipo M; Rashidghamat E; Tziotzios C; Onoufriadis A; Chen M; Chan L; Farzaneh F; Del Rio M; Tolar J; Bauer JW; Larcher F; Antoniou MN; Hovnanian A; Thrasher AJ; Mellerio JE; Qasim W; McGrath JA
JCI Insight; 2019 Jun; 4(11):. PubMed ID: 31167965
[TBL] [Abstract][Full Text] [Related]
6. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M
J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931
[TBL] [Abstract][Full Text] [Related]
7. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
[TBL] [Abstract][Full Text] [Related]
8. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
[TBL] [Abstract][Full Text] [Related]
9. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
[TBL] [Abstract][Full Text] [Related]
10. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.
Latella MC; Cocchiarella F; De Rosa L; Turchiano G; Gonçalves MAFV; Larcher F; De Luca M; Recchia A
J Invest Dermatol; 2017 Apr; 137(4):836-844. PubMed ID: 28027893
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.
Cutlar L; Greiser U; Wang W
Exp Dermatol; 2014 Jan; 23(1):1-6. PubMed ID: 24107073
[TBL] [Abstract][Full Text] [Related]
12. Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.
Wang X; Alshehri F; Manzanares D; Li Y; He Z; Qiu B; Zeng M; A S; Lara-Sáez I; Wang W
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884578
[TBL] [Abstract][Full Text] [Related]
13. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.
Twaroski K; Eide C; Riddle MJ; Xia L; Lees CJ; Chen W; Mathews W; Keene DR; McGrath JA; Tolar J
Br J Dermatol; 2019 Dec; 181(6):1247-1253. PubMed ID: 30924923
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
[TBL] [Abstract][Full Text] [Related]
15. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
Gurevich I; Agarwal P; Zhang P; Dolorito JA; Oliver S; Liu H; Reitze N; Sarma N; Bagci IS; Sridhar K; Kakarla V; Yenamandra VK; O'Malley M; Prisco M; Tufa SF; Keene DR; South AP; Krishnan SM; Marinkovich MP
Nat Med; 2022 Apr; 28(4):780-788. PubMed ID: 35347281
[TBL] [Abstract][Full Text] [Related]
16. Pathomechanisms of Altered Wound Healing in Recessive Dystrophic Epidermolysis Bullosa.
Cianfarani F; Zambruno G; Castiglia D; Odorisio T
Am J Pathol; 2017 Jul; 187(7):1445-1453. PubMed ID: 28460207
[TBL] [Abstract][Full Text] [Related]
17. An RNA-targeted therapy for dystrophic epidermolysis bullosa.
Peking P; Koller U; Duarte B; Murillas R; Wolf S; Maetzig T; Rothe M; Kocher T; García M; Brachtl G; Schambach A; Larcher F; Reichelt J; Bauer JW; Murauer EM
Nucleic Acids Res; 2017 Sep; 45(17):10259-10269. PubMed ID: 28973459
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE
Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907
[TBL] [Abstract][Full Text] [Related]
19. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa.
Murauer EM; Gache Y; Gratz IK; Klausegger A; Muss W; Gruber C; Meneguzzi G; Hintner H; Bauer JW
J Invest Dermatol; 2011 Jan; 131(1):74-83. PubMed ID: 20720561
[TBL] [Abstract][Full Text] [Related]
20. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
Guide SV; Gonzalez ME; Bağcı IS; Agostini B; Chen H; Feeney G; Steimer M; Kapadia B; Sridhar K; Quesada Sanchez L; Gonzalez F; Van Ligten M; Parry TJ; Chitra S; Kammerman LA; Krishnan S; Marinkovich MP
N Engl J Med; 2022 Dec; 387(24):2211-2219. PubMed ID: 36516090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
